• Trials and Research

  Cyxone Launches Phase 1 Trial Assessing the Effects of T20K for MS

  Posted by MS News Today Moderator on July 1, 2019 at 1:11 pm

  

  Cyxone has launched the first-in-human Phase 1 clinical trial assessing the effects of T20K, its therapeutic candidate for MS, in a group of healthy volunteers. Click here to read more about the trial.

  What do you think of this news?

  replied 4 years, 10 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply